iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 305,211 shares, an increase of 92.3% from the October 15th total of 158,754 shares. Based on an average trading volume of 412,744 shares, the short-interest ratio is currently 0.7 days. Currently, 13.8% of the shares of the company are sold short.
iSpecimen Stock Down 5.4%
Shares of iSpecimen stock traded down $0.04 on Friday, reaching $0.66. 113,271 shares of the stock were exchanged, compared to its average volume of 305,883. iSpecimen has a twelve month low of $0.63 and a twelve month high of $27.44. The firm has a market capitalization of $1.66 million, a price-to-earnings ratio of -0.01 and a beta of 1.54. The business has a 50 day moving average price of $1.07 and a two-hundred day moving average price of $4.25.
iSpecimen (NASDAQ:ISPC – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.98) EPS for the quarter. iSpecimen had a negative net margin of 2,445.40% and a negative return on equity of 524.39%. The firm had revenue of $0.15 million during the quarter.
Wall Street Analysts Forecast Growth
View Our Latest Report on ISPC
About iSpecimen
iSpecimen, Inc. (NASDAQ: ISPC) operates a technology-enabled marketplace that connects life sciences researchers with sources of human biospecimens. Its platform is designed to help pharmaceutical, biotechnology, diagnostic and academic organizations identify, search for and procure biological samples and associated clinical data for research and development. The company’s offerings support access to a range of specimen types, including blood, tissue and other human-derived samples obtained through healthcare providers, laboratories, biobanks and research institutions. iSpecimen also facilitates custom collection programs and related sourcing services intended to help customers obtain specimens that meet specific scientific, demographic and clinical requirements.
See Also
- Five stocks we like better than iSpecimen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
